|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liver histology in ICU patients dying from sepsis:A clinico-pathological study显示文摘AIM:To determine end-stage pathologic changes in the liver of septic patients dying in the intensive care unit. METHODS: Needle liver biopsies obtained immediately after death from 15 consecutive patients with sepsis and no underlying liver disease were subjected to routine histological examination. Liver function tests and clinical monitoring measurements were also recorded. RESULTS: Liver biochemistries were increased in the majority of patients before death. Histology of liver bi- opsy specimens showed portal inflammation in 73.3%, centrilobular necrosis in 80%, lobular inflammation in 66.7%, hepatocellular apoptosis in 66.6% and cholan- gitis/cholangiolitis in 20% of patients. Mixed hepatitic/ cholestatic type of liver injury was observed in 6/15 (40%) patients and hepatitc in 9/15 (60%). Steatosis was ob- served in 11/15 (73.3%) patients affecting 5%-80% of liver parenchyma. Among the histological features, the presence of portal inflammation in liver biopsy was as- sociated with increased hospitalization in the ICU prior death (P = 0.026). CONCLUSION: Features of hepatitis and steatosis arethe main histological findings in the liver in the majority of patients dying from sepsis. | John Koskinas Ilias P Gomatos Dina G Tiniakos Nikolaos Memos Maria Boutsikou Aspasia Garatzioti Athanasios Archimandritis Alexander Betrosian | 2008 | World Journal of Gastroenterology2008，14，9： | 8 |
| 2 | Meta-analysis of subtotal stomach-preserving pancreaticoduodenectomy vs pylorus preserving pancreaticoduodenectomy显示文摘AIM: To investigate the differences in outcome following pylorus preserving pancreaticoduodenectomy(PPPD) and subtotal stomach-preserving pancreaticoduodenectomy(SSPPD).METHODS: Major databases including Pub Med(Medline), EMBASE and Science Citation Index Expanded and the Cochrane Central Register of Controlled Trials(CENTRAL) in The Cochrane Library were searched for comparative studies between patients with PPPD and SSPPD published between January 1978 and July 2014. Studies were selected based on specific inclusion and exclusion criteria. The primary outcome was delayed gastric emptying(DGE). Secondary outcomes included operation time, intraoperative blood loss, pancreatic fistula, postoperative hemorrhage, intraabdominal abscess, wound infection, time to starting liquid diet, time to starting solid diet, period of nasogastric intubation, reinsertion of nasogastric tube, mortality and hospital stay. The pooled odds ratios(OR) or weighted mean difference(WMD) with 95% confidence intervals(95%CI) were calculated using either a fixed-effects or random-effects model. RESULTS: Eight comparative studies recruiting 650 patients were analyzed, which include two RCTs, one non-randomized prospective and 5 retrospective trial designs. Patients undergoing SSPPD experienced significantly lower rates of DGE(OR = 2.75; 95%CI: 1.75-4.30, P < 0.00001) and a shorter period of nasogastric intubation(OR = 2.68; 95%CI: 0.77-4.58,P < 0.00001), with a tendency towards shorter time to liquid(WMD = 2.97, 95%CI:-0.46-7.83; P = 0.09) and solid diets(WMD = 3.69, 95%CI:-0.46-7.83; P = 0.08) as well as shorter inpatient stay(WMD = 3.92, 95%CI:-0.37-8.22; P = 0.07), although these latter three did not reach statistical significance. PPPD, however, was associated with less intraoperative blood loss than SSPPD [WMD =-217.70, 95%CI:-429.77-(-5.63); P = 0.04]. There were no differences in other parameters between the two approaches, including operative time(WMD =-5.30, 95%CI:-43.44-32.84; P = 0.79), pancreatic fistula(OR = 0.91; 95%CI: 0.56-1.49; P = 0.70), postoperative hemorrhage(OR = 0.51; 95%CI: 0.15-1.74; P = 0.29), intraabdominal abscess(OR = 1.05; 95%CI: 0.54-2.05; P = 0.89), wound infection(OR = 0.88; 95%CI: 0.39-1.97; P = 0.75), reinsertion of nasogastric tube(OR = 1.90; 95%CI: 0.91-3.97; P = 0.09) and mortality(OR = 0.31; 95%CI: 0.05-2.01; P = 0.22).CONCLUSION: SSPPD may improve intraoperative and short-term postoperative outcomes compared to PPPD, especially DGE. However, these findings need to be further ascertained by well-designed randomized controlled trials. | Wei Huang Jun-Jie Xiong Mei-Hua Wan Peter Szatmary Shameena Bharucha Ilias Gomatos Quentin M Nunes Qing Xia Robert Sutton Xu-Bao Liu | 2015 | World Journal of Gastroenterology2015，21，20： | 8 |
| 3 | Prophylactic intra-peritoneal drain placement following pancreaticoduodenectomy:A systematic review and metaanalysis显示文摘AIM:To conduct a meta-analysis comparing outcomes after pancreaticoduodenectomy(PD)with or without prophylactic drainage.METHODS:Relevant comparative randomized and nonrandomized studies were systemically searched based on specific inclusion and exclusion criteria.Postoperative outcomes were compared between patients with and those without routine drainage.Pooled odds ratios(OR)with 95%CI were calculated using either fixed effects or random effects models.RESULTS:One randomized controlled trial and four non-randomized comparative studies recruiting 1728patients were analyzed.Patients without prophylactic drainage after PD had significantly higher mortality(OR=2.32,95%CI:1.11-4.85;P=0.02),despite the fact that they were associated with fewer overall complications(OR=0.62,95%CI:0.48-0.82;P=0.00),major complications(OR=0.75,95%CI:0.60-0.93;P=0.01)and readmissions(OR=0.77,95%CI:0.60-0.98;P=0.04).There were no significant differences in the rates of pancreatic fistula,intraabdominal abscesses,postpancreatectomy hemorrhage,biliary fistula,delayed gastric emptying,reoperation or radiologic-guided drains between the two groups.CONCLUSION:Indiscriminate abandonment of intraabdominal drainage following PD is associated with greater mortality,but lower complication rates.Future randomized trials should compare routine vs selective drainage. | Yi-Chao Wang Peter Szatmary Jing-Qiang Zhu Jun-Jie Xiong Wei Huang Ilias Gomatos Quentin M Nunes Robert Sutton Xu-Bao Liu | 2015 | World Journal of Gastroenterology2015，21，8： | 7 |
| 4 | Molecular markers(PECAM-1,ICAM-3,HLA-DR)determine prognosis in primary non-Hodgkin's gastric lymphoma patients显示文摘瞄准:与主要 non-Hodgkin 的胃的淋巴瘤在病人调查 PECAM-1, ICAM-3 和 HLA 医生抗原的预示的意义。方法:我们免疫组织化学地在 36 个 B 房间麦芽类型主要胃的淋巴瘤病人学习了 PECAM-1, ICAM-3 和 HLA 医生抗原表示。十非恶意并且十个健康胃的织物标本被用作控制。Clinicopathological 和幸存数据与染色的结果被相关。结果:HLA 医生抗原表示在 33 个胃的淋巴瘤病人(91.7%) 和 6 个非恶意的病人(54.5%) 被检测。PECAM-1 染色了 10 个病人(27.8%) 的肿瘤房间, 9 个病人(25%) 的 endothelial 并且煽动性有良性的胃的疾病的 4 个病人(40%) 渗入。ICAM-3 表示在 17 个病人(47.2%) 的肿瘤房间上被观察,当 5 个非恶意的病人(50%) 被染色时积极也。任何一个都没为任何学习的基因健康控制被染色。在里面多,变量分析, HLA 医生抗原和 PECAM-1 被证明是与联系的统计上重要的独立预示的因素一赞成并且不利预后分别地(P=0.009 和 P=0.003 ) 。在 univariate 分析, PECAM-1 (+)/ICAM-3 (-) 和 HLA 医生(-)/ICAM-3 (-) 病人与确切相反的基因表示模式与那些相比展出了显著地减少的全面幸存(P=0.0041 和 P=0.0091,分别地) 。是 HLA 医生(+)/ICAM-3 (+)/PECAM-1 (-)(n=8 ) 的那些病人让显著地更高的幸存与这个组(n=24 )(P=0.0289 ) 的其余部分相比评价。结论:PECAM-1, ICAM-3 和 HLA 医生分别地是肿瘤扩大潜力和主人免疫者监视的代表性的标记。他们的联合使用可以帮助我们识别能得益于更好攻击的治疗学的协议的高风险的病人。 | Alexander Darom Ilias P Gomatos Emmanuel Leandros Emmu Chatzigianni Dimitris Panousopoulos Manousos M Konstadoulakis George Androulakis | 2006 | World Journal of Gastroenterology2006，12，12： | 4 |
| 5 | Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma 显示文摘 | GEORGIOU A GOMATOS I P FEREKIDIS E | 2001 | Eur J Surg Oncol2001，27，： | 1 |
| 6 | Cell kinetics and apoptosis in laryngeal carcinoma patients显示文摘 | Georgiou A Gomatos I P Pararas N B Giotakis J Ferekidis E | 2003 | Ann Otol Rhinol Laryngol2003，112，： | 1 |
| 7 | Prognostic value of bax, bcl -2, and p53 staining in primary osteosarcoma显示文摘 | Kaseta MK Khaldi L Gomatos IP | 2008 | J Surg Oncol2008，97，3： | 1 |
| 8 | Cell ki-netics and apoptosis inaryngeal carcinoma patients显示文摘 | Georgiou A Gomatos IP Pararas NB | 2003 | Ann Otol Rhino Aryngol2003，112，： | 1 |
| 9 | Ag- gressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience 显示文摘 | Konstadoulakis MM Roayaie S Gomatos IP | 2008 | Am J Surg2008，196，2： | 1 |
| 10 | Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Au- dit of a single center' s experience显示文摘 | Konstadoulakis MM Roayaie S Gomatos IP | 2008 | Am J Surg2008，196，2： | 1 |
| 11 | Phylogenetic analysis of hepatitis E virus isolates from Egypt显示文摘 | TSAREV SA BINN LN GOMATOS PJ | 1999 | J Med Virol1999，57，： | 1 |
| 12 | Cell kinetics and apoptosis in laryngeal carcinoma patients显示文摘 | GEORGIOU A GOMATOS IP PARARAS NB | 2003 | Ann Otol Rhinol Laryngol2003，112，3： | 1 |
| 13 | Aggressive surgical resec-tion for hilar cholangiocarcinoma:is it justified? Auditof a single center's experience显示文摘 | Konstadoulakis M M Roayaie S? Gomatos I P LabowD Fiel M I Miller C M | 2008 | Am J Surg2008，196，： | 1 |
| 14 | Cell kinetics and apoptosis in aryngeal carcinoma patients显示文摘 | Georgiou A Gomatos IP Pararas NB | 2003 | Ann Otolrhinoaryngol2003，112，： | 1 |
| 15 | Complete endoscopic axillary lymph node dissection without liposuction for breast cancer:initial experience and mid-term outcome显示文摘 | Gomatos I P Filippakis G Albanopoulos K | 2006 | Surg Laparosc Endosc Percutan Tech2006，16，： | 1 |
| 16 | Phylogenetic analysis of hepatitis E virus isolates from Egypt显示文摘 | Tsarev S A Binn N Gomatos P J | 1999 | J Med Virol1999，57，： | 1 |
| 17 | Complete endoscopic axillary lymph node dissection without liposuction for breast cancer:initial experience and mid-term outcome显示文摘 | Gomatos IP Filippakis G Albanopoulos K | 2006 | Surg Laparosc Endosc Percutan Tech2006，16，4： | 1 |
| 18 | Pelvic isolation with two Gore-tex dual-mesh pieces for a recurrent complicated enterovescicocervical fistula in a patient irradiated for cervical cancer显示文摘 | Leandros E Antonakis PT Gomatos I | 2009 | Am Surg2009，75，11： | 1 |
| 19 | Aggressive surgical resection for hilar cholangiocarcinoma:is it justified? Audit of a single center's experience显示文摘 | Konstadoulakis MM Roayaie S Gomatos IP | 2008 | Am J Surg2008，196，2： | 1 |
| 20 | Complete endoscopic axillary lymph node dissection without liposuction for breast cancer:initial experience and mid-term outcome 显示文摘 | Gomatos IP Filippakis G Albanopoulos K | 2006 | Surg Laparosc Endosc Percutan Tech2006，16，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员